Palisade Bio (PALI) EBIT Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Palisade Bio | 439.25 Mn | 309.68 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -40.63% |
| Dec 31, 2025 | -25.20% |
| Sep 30, 2025 | -9.98% |
| Jun 30, 2025 | -9.08% |
| Mar 31, 2025 | -3.02% |
| Dec 31, 2024 | -9.66% |
| Sep 30, 2024 | -11.08% |
| Jun 30, 2024 | -17.03% |
| Mar 31, 2024 | -8.38% |
| Dec 31, 2023 | -11.81% |
| Sep 30, 2023 | -12.65% |
| Jun 30, 2023 | -12.27% |
| Mar 31, 2023 | -1.49% |
| Dec 31, 2022 | -11.14% |
| Sep 30, 2022 | -11.26% |
| Jun 30, 2022 | 3.27% |
| Mar 31, 2022 | 1.68% |
| Dec 31, 2021 | 6.55% |
| Sep 30, 2021 | 9.31% |
| Jun 30, 2021 | -53.67% |
| Mar 31, 2021 | 20.71% |
| Dec 31, 2020 | 5.70% |
| Sep 30, 2020 | 18.97% |
| Jun 30, 2020 | 18.10% |
| Mar 31, 2020 | 15.47% |
| Dec 31, 2019 | 14.40% |
| Sep 30, 2019 | 12.35% |
| Jun 30, 2019 | 11.39% |
| Mar 31, 2019 | 13.85% |
| Dec 31, 2018 | 8.16% |
| Sep 30, 2018 | 10.54% |
| Jun 30, 2018 | 8.97% |
| Mar 31, 2018 | 4.07% |
| Dec 31, 2017 | 3.61% |
| Sep 30, 2017 | -0.04% |
| Jun 30, 2017 | -12.10% |
| Mar 31, 2017 | -11.43% |
| Dec 31, 2016 | -17.14% |
| Sep 30, 2016 | -8.81% |
| Jun 30, 2016 | -0.89% |
| Mar 31, 2016 | -12.00% |
| Dec 31, 2015 | -4.76% |
| Sep 30, 2015 | -5.78% |
| Jun 30, 2015 | -3.55% |